Fulcrum Therapeutics (FULC)
NASDAQ:FULC
Want to see FULC full AI Analyst Report?
Earnings Data
Report Date
Aug 05, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.28Last Year’s EPS
-0.28Same Quarter Last Year
Moderate Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong positive clinical momentum for potociredir — notably a large, rapid increase in HbF, early VOC reduction signals and a clean safety profile — paired with a solid balance sheet and a clear plan for regulatory interactions and a potential registration-enabling trial. Offsetting risks include modestly higher operating losses and expenses, a quarterly cash decline (while runway remains into 2029), delayed availability of meaningful long-term OLE data (likely into 2027), ongoing regulatory uncertainty about surrogate endpoints and emerging competition in the oral HbF inducer space. Overall, the clinical and financial highlights outweigh the operational and regulatory uncertainties.Company Guidance
Robust HbF Increase in Phase Ib PIONEER
Potociredir 20 mg once daily produced an increase in fetal hemoglobin (HbF) from 7.1% at baseline to 19.3% at Week 12 — an absolute increase of 12.2 percentage points (≈171.8% relative increase). Additional signals included improvements in markers of hemolysis and anemia and continued progression toward pancellular HbF expression.
Meaningful Reduction in VOCs in Severe Cohort
In the PIONEER cohort, 7 of 12 patients (58.3%) experienced no vaso-occlusive crises (VOCs) during the 12-week treatment period, indicating an early clinical benefit signal on VOC frequency in a severe patient population.
Favorable Safety Profile to Date
Potociredir was generally well tolerated in the Phase Ib PIONEER trial with no treatment-related serious adverse events reported to date.
Open-Label Long-Term Dosing Initiated
An open-label long-term dosing (OLE) study was initiated and the first patient enrolled; the OLE targets the 17 U.S.-based patients from prior cohorts (3b and 4) to assess long-term safety, durability of response and effects of reinitiation of therapy.
Planned Next-Stage Development and Regulatory Engagement
Fulcrum expects an end-of-phase meeting with the FDA this quarter and plans to initiate a potential registration-enabling trial in the second half of 2026 pending FDA feedback, reflecting an actionable path toward late-stage development.
Strong Balance Sheet and Multi-Year Runway
Cash, cash equivalents and marketable securities totaled $333.3 million as of March 31, 2026 (vs. $352.3M on Dec 31, 2025). Management expects existing funds to provide runway into 2029 to advance potociredir through the next phase of clinical development.
Corporate and Scientific Strengthening
Welcomed Josh Lehrer to the Board (bringing deep sickle cell experience). Company maintains dedicated discovery efforts (company ~60–65 employees; ~20–25 focused on discovery) to progress next-generation oral HbF inducers.
FULC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FULC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 27, 2026 | $7.84 | $7.72 | -1.53% |
Feb 24, 2026 | $10.89 | $8.58 | -21.21% |
Oct 29, 2025 | $10.00 | $9.36 | -6.40% |
Jul 29, 2025 | $7.81 | $7.59 | -2.82% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Fulcrum Therapeutics (FULC) report earnings?
Fulcrum Therapeutics (FULC) is schdueled to report earning on Aug 05, 2026, Before Open (Confirmed).
What is Fulcrum Therapeutics (FULC) earnings time?
Fulcrum Therapeutics (FULC) earnings time is at Aug 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FULC EPS forecast?
FULC EPS forecast for the fiscal quarter 2026 (Q2) is -0.28.